|Bid||8.32 x 1200|
|Ask||8.59 x 800|
|Day's Range||8.12 - 8.64|
|52 Week Range||3.81 - 8.75|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Oct 31, 2014|
|1y Target Est||N/A|
Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
With the business potentially at an important milestone, we thought we'd take a closer look at Paratek Pharmaceuticals...
A press release for the company's fourth-quarter and full-year results was issued earlier today, and we've also posted slides on our website that will be referred to on this call. Participants on today's call are Evan Loh, CEO; Adam Woodrow, president and chief commercial officer; Randy Brenner, chief development and regulatory officer; Michael Bigham, executive chairman; and Sarah Higgins, vice president of finance, controller, and principal accounting officer, will also be available for questions.